Unlike tofacitinib (359) and baricitinib (380), upadacitinib is engineered to be selective for JAK1 and serves as the second-generation JAK inhibitor approved by FDA in 2019 for RA (381). The gene discussed is JAK1; the disease is rheumatoid arthritis.